跳至主要内容
临床试验/JPRN-UMIN000022213
JPRN-UMIN000022213已完成未知

The association of Cytokine /chemokine profiles with the clinical outcome and safety in relapsed/refractory multiple myeloma patients treated with lenalidomide plus dexamethasone - Cytokine /chemokine profiles in relapsed/refractory multiple myeloma patients treated with lenalidomide plus dexamethasone

Hamamatsu University School of Medicine0 个研究点目标入组 20 人开始时间: 2016年5月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Previous treatment with lenalidomide 2.Hypersensitivity to lenalidomide and/or dexamethasone 3.non-secretory myeloma, solitary plasmacytoma, plasma cell leukemia, of POEMS syndrome 4.Positivity of HBs antigen or, HCV or HIV antibody 5.Uncontrollable liver dysfunction, renal dysfunction, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, hypertension and infection 6.Double cancer requiring treatments 7.Psychoneurotic disorder, depression state or history 8.Patients with pregnancy, patients who may be pregnant, or patients during lactation 9.Pulomonary fibrosis, interstitial pneumonitis or interstitial shadow on chest CT, even if no symptom 10.Ineligible patient by physicians decision

研究者

相似试验